Diabetes treatment patterns and goal achievement in primary diabetes care (DiaRegis) - study protocol and patient characteristics at baseline

Cardiovascular Diabetology

Volumn 9, Issue , 2010, Pages

  Bramlage, Peter ^a   Binz, Christiane ^b   Gitt, Anselm K ^c   Krekler, Michael ^b   Plate, Tanja ^d   Deeg, Evelin ^c   Tschöpe, Diethelm ^e  

^a Institute for Cardiovascular Pharmacology and Epidemiology   (Germany)

^b BRISTOL MYERS SQUIBB   (United States)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d ASTRAZENECA   (United Kingdom)

^e RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GLUCOSIDASE INHIBITOR; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLITAZONE DERIVATIVE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; METFORMIN; ORAL ANTIDIABETIC AGENT; SULFONYLUREA; ANTIDIABETIC AGENT; SULFONYLUREA DERIVATIVE;

ADULT; ARTERY DISEASE; ARTICLE; BODY MASS; CLINICAL TRIAL; COMORBIDITY; CORONARY ARTERY DISEASE; DISEASE DURATION; DISEASE REGISTRY; DISEASE SEVERITY; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HEART FAILURE; HUMAN; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MONOTHERAPY; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PERIPHERAL NEUROPATHY; PRIMARY MEDICAL CARE; PROSPECTIVE STUDY; SIDE EFFECT; TREATMENT FAILURE; TREATMENT INDICATION; WAIST CIRCUMFERENCE; WEIGHT GAIN; CHEMICALLY INDUCED DISORDER; DIABETES MELLITUS; GEOGRAPHIC INFORMATION SYSTEM; GERMANY; PRIMARY HEALTH CARE; REGISTER; RISK FACTOR; STATISTICS;

ADULT; COMORBIDITY; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; FEMALE; FOLLOW-UP STUDIES; GEOGRAPHIC INFORMATION SYSTEMS; GERMANY; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; PRIMARY HEALTH CARE; REGISTRIES; RISK FACTORS; SULFONYLUREA COMPOUNDS;

EID: 77956585776     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-9-53     Document Type: Article

References (39)

1. Schernthaner G. Diabetes and Cardiovascular Disease: Is intensive glucose control beneficial or deadly? Lessons from ACCORD, ADVANCE, VADT, UKPDS, PROactive, and NICE-SUGAR. Wien Med Wochenschr 2010, 160(1-2):8-19. 10.1007/s10354-010-0748-7, 20229156.
2. Matthaei S, Bierwirth R, Fritsche A, Gallwitz B, Haring HU, Joost HG, Kellerer M, Kloos C, Kunt T, Nauck M, Schernthaner G, Siegel E, Thienel F. Medical antihyperglycaemic treatment of type 2 diabetes mellitus: update of the evidence-based guideline of the German Diabetes Association. Exp Clin Endocrinol Diabetes 2009, 117(9):522-557. 10.1055/s-0029-1239559, 19876795.
3. UKPDS Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998, 352(9131):854-865. 10.1016/S0140-6736(98)07037-8, 9742977, UKPDS.
4. Gerstein HC, Miller ME, Byington RP, Goff DC, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH, Probstfield JL, Simons-Morton DG, Friedewald WT. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008, 358(24):2545-2559. 10.1056/NEJMoa0802743, 18539917.
5. Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbee D, Hamet P, Harrap S, Heller S, Liu L, Mancia G, Mogensen CE, Pan C, Poulter N, Rodgers A, Williams B, Bompoint S, de Galan BE, Joshi R, Travert F. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008, 358(24):2560-2572. 10.1056/NEJMoa0802987, 18539916.
6. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, Zieve FJ, Marks J, Davis SN, Hayward R, Warren SR, Goldman S, McCarren M, Vitek ME, Henderson WG, Huang GD. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009, 360(2):129-139. 10.1056/NEJMoa0808431, 19092145.
7. FDA Guidance for Industry. Diabetes Mellitus - Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes. 2008, FDA., http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM071627.pdf
8. Pfeifer MA, Halter JB, Porte D. Insulin secretion in diabetes mellitus. Am J Med 1981, 70(3):579-588. 10.1016/0002-9343(81)90579-9, 7011013.
9. Avignon A, Radauceanu A, Monnier L. Nonfasting plasma glucose is a better marker of diabetic control than fasting plasma glucose in type 2 diabetes. Diabetes Care 1997, 20(12):1822-1826. 10.2337/diacare.20.12.1822, 9405900.
10. Bouma M, Dekker JH, de Sonnaville JJ, van der Does FE, de Vries H, Kriegsman DM, Kostense PJ, Heine RJ, van Eijk JT. How valid is fasting plasma glucose as a parameter of glycemic control in non-insulin-using patients with type 2 diabetes?. Diabetes Care 1999, 22(6):904-907. 10.2337/diacare.22.6.904, 10372239.
11. Verges B. [The impact of regulation of postprandial glucose in practice]. Diabetes Metab 1999, 25(Suppl 7):22-25.
12. Soonthornpun S, Rattarasarn C, Leelawattana R, Setasuban W. Postprandial plasma glucose: a good index of glycemic control in type 2 diabetic patients having near-normal fasting glucose levels. Diabetes Res Clin Pract 1999, 46(1):23-27. 10.1016/S0168-8227(99)00061-3, 10580612.
13. Feinglos MN, Thacker CH, English J, Bethel MA, Lane JD. Modification of postprandial hyperglycemia with insulin lispro improves glucose control in patients with type 2 diabetes. Diabetes Care 1997, 20(10):1539-1542. 10.2337/diacare.20.10.1539, 9314631.
14. Bastyr EJ, Stuart CA, Brodows RG, Schwartz S, Graf CJ, Zagar A, Robertson KE. Therapy focused on lowering postprandial glucose, not fasting glucose, may be superior for lowering HbA1c. IOEZ Study Group. Diabetes Care 2000, 23(9):1236-1241. 10.2337/diacare.23.9.1236, 10977012.
15. Phung OJ, Scholle JM, Talwar M, Coleman CI. Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes. JAMA 2010, 303(14):1410-1418. 10.1001/jama.2010.405, 20388897.
16. Dluhy RG, McMahon GT. Intensive glycemic control in the ACCORD and ADVANCE trials. N Engl J Med 2008, 358(24):2630-2633. 10.1056/NEJMe0804182, 18539918.
17. Cox D, Gonder-Frederick L, McCall A, Kovatchev B, Clarke W. The effects of glucose fluctuation on cognitive function and QOL: the functional costs of hypoglycaemia and hyperglycaemia among adults with type 1 or type 2 diabetes. Int J Clin Pract Suppl 2002(129):20-26.
18. Ferriss JB, Webb D, Chaturvedi N, Fuller JH, Idzior-Walus B. Weight gain is associated with improved glycaemic control but with adverse changes in plasma lipids and blood pressure isn Type 1 diabetes. Diabet Med 2006, 23(5):557-564. 10.1111/j.1464-5491.2006.01847.x, 16681565.
19. Prato SD, LaSalle J, Matthaei S, Bailey CJ. Tailoring treatment to the individual in type 2 diabetes practical guidance from the Global Partnership for Effective Diabetes Management. Int J Clin Pract 2010, 64(3):295-304. 10.1111/j.1742-1241.2009.02227.x, 2814090, 20456169.
20. Fritsche A, Haring H. At last, a weight neutral insulin?. Int J Obes Relat Metab Disord 2004, 28(Suppl 2):S41-46. 10.1038/sj.ijo.0802749, 15306837.
21. Martin S, Schramm W, Schneider B, Neeser K, Weber C, Lodwig V, Heinemann L, Scherbaum WA, Kolb H. Epidemiology of complications and total treatment costs from diagnosis of Type 2 diabetes in Germany (ROSSO 4). Exp Clin Endocrinol Diabetes 2007, 115(8):495-501. 10.1055/s-2007-981470, 17853332.
22. Liebl A, Neiss A, Spannheimer A, Reitberger U, Wagner T, Gortz A. Kosten des Typ-2-Diabetes in Deutschland. Ergebnisse der CODE-2-Studie. Dtsch Med Wochenschr 2001, 126(20):585-589. 10.1055/s-2001-14102, 11402924.
23. Koster I, von Ferber L, Ihle P, Schubert I, Hauner H. The cost burden of diabetes mellitus: the evidence from Germany--the CoDiM study. Diabetologia 2006, 49(7):1498-1504. 10.1007/s00125-006-0277-5, 16752168.
24. von Ferber L, Koster I, Hauner H. Medical costs of diabetic complications total costs and excess costs by age and type of treatment results of the German CoDiM Study. Exp Clin Endocrinol Diabetes 2007, 115(2):97-104. 10.1055/s-2007-949152, 17318768.
25. Verband Forschender Arzneimittelhersteller. Prospektives Deutsches Register zur Dokumentation der ambulanten Therapie des Diabetes und der Zielwerterreichung im klinischen Alltag (DiaRegis). , http://www.vfa.de/de/arzneimittel-forschung/datenbanken-zu-arzneimitteln/nisdb/nis-details/_303
26. Wittchen HU, Krause P, Hofler M, Pfister H, Kupper B, Pittrow D, Bramlage P, Unger T, Sharma AM, Ritz E, Goke B, Lehnert H, Tschope D, Kirch W. [Aim, design and methods of the "Hypertension and diabetes screening and awareness" -- (HYDRA) study]. Fortschritte der Medizin 2003, 121(Suppl 1):2-11.
27. Wittchen HU, Glaesmer H, Marz W, Stalla G, Lehnert H, Zeiher AM, Silber S, Koch U, Bohler S, Pittrow D, Ruf G. Cardiovascular risk factors in primary care: methods and baseline prevalence rates--the DETECT program. Curr Med Res Opin 2005, 21(4):619-630. 10.1185/030079905X38187, 15899112.
28. Liebl A, Mata M, Eschwege E. Evaluation of risk factors for development of complications in Type II diabetes in Europe. Diabetologia 2002, 45(7):S23-28.
29. Liebl A, Neiss A, Spannheimer A, Reitberger U, Wieseler B, Stammer H, Goertz A. Complications, co-morbidity, and blood glucose control in type 2 diabetes mellitus patients in Germany--results from the CODE-2 study. Exp Clin Endocrinol Diabetes 2002, 110(1):10-16. 10.1055/s-2002-19988, 11835119.
30. Martin S, Schneider B, Heinemann L, Lodwig V, Kurth HJ, Kolb H, Scherbaum WA. Self-monitoring of blood glucose in type 2 diabetes and long-term outcome: an epidemiological cohort study. Diabetologia 2006, 49(2):271-278. 10.1007/s00125-005-0083-5, 16362814.
31. Krone W, Bohm M, Wöhrmann APA, Bestehorn K. Erhebung und Verbesserung der Behandlungssituation von Patienten mit Diabetes mellitus. Das DUTY-Register. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2004, 47(6):540-546.
32. Ott P, Köhler C, Hanefeld M. Baseline data of the Diabetes in Germany study (DIG). Prospective 4-year study on the epidemiology of type-2 diabetes in Germany. Diabetologe 2006, 2(Suppl. 1):S44-S48.
33. Hanefeld M, Koehler C, Gallo S, Benke I, Ott P. Impact of the individual components of the metabolic syndrome and their different combinations on the prevalence of atherosclerotic vascular disease in type 2 diabetes: the Diabetes in Germany (DIG) study. Cardiovasc Diabetol 2007, 6:13. 10.1186/1475-2840-6-13, 1871572, 17462080.
34. Towae F, Bauer T, Tschöpe D, Schnell O, Standl E, Zahn R, Gitt AK. Recognition of abnormal glucose metabolism and its impact on treatment in patients with acute myocardial infarction in Germany: Results of the SWEETHEART registry. Deutsche Gesellschaft für Kardiologie 2010, Mannheim, Germany.
35. Price HC, Tucker L, Griffin SJ, Holman RR. The impact of individualised cardiovascular disease (CVD) risk estimates and lifestyle advice on physical activity in individuals at high risk of CVD: a pilot 2 × 2 factorial understanding risk trial. Cardiovasc Diabetol 2008, 7:21. 10.1186/1475-2840-7-21, 2490674, 18637168.
36. Valdivielso P, Rioja J, Garcia-Arias C, Sanchez-Chaparro MA, Gonzalez-Santos P. Omega 3 fatty acids induce a marked reduction of apolipoprotein B48 when added to fluvastatin in patients with type 2 diabetes and mixed hyperlipidemia: a preliminary report. Cardiovasc Diabetol 2009, 8:1. 10.1186/1475-2840-8-1, 2631503, 19133114.
37. Moebus S, Hanisch JU, Aidelsburger P, Bramlage P, Wasem J, Jöckel K-H. Impact of four different definitions used for assessment of the prevalence of metabolic syndrome in a primary health care setting. The German Metabolic and Cardiovascular Risk Project (GEMCAS). Cardiovasc Diabetol 2007, 6(1):22. 10.1186/1475-2840-6-22, 2031874, 17822558.
38. Moebus S, Balijepalli C, Losch C, Gores L, von Stritzky B, Bramlage P, Wasem J, Jockel KH. Age- and sex-specific prevalence and ten-year risk for cardiovascular disease of all 16 risk factor combinations of the metabolic syndrome - A cross-sectional study. Cardiovasc Diabetol 2010, 9(1):34. 10.1186/1475-2840-9-34, 2929217, 20696055.
39. Wittchen HU, Krause P, Hofler M, Pfister H, Ritz E, Goke B, Lehnert H, Tschope D, Kirch W, Pittrow D, Sharma AM, Bramlage P, Kupper B, Unger T. [Hypertension, diabetes mellitus and comorbidity in primary care]. Fortschritte der Medizin 2003, 121(Suppl 1):19-27.